Safety of Tofacitinib in Ulcerative Colitis
Part of Digestive system clinical trials.
This study follows people with moderately to severely active ulcerative colitis who are taking the medication tofacitinib (Xeljanz). It aims to track any safety concerns in a real-world setting, using information already collected in a European registry (UR-CARE).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with ulcerative colitis by a doctor.
- You are part of the UR-CARE registry and have at least 12 months of medical history in that registry.
- You have signed a consent form allowing your data to be used for research.
- You have never been diagnosed with Crohn's disease or an unspecified type of inflammatory bowel disease (IBD).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking tofacitinib alone works as well as taking tofacitinib with mesalamine for people with ulcerative colitis who are already in remission. It aims to see if one medication can be stopped without causing a flare-up.
This study looks at how tofacitinib (and related medicines) may affect clotting and blood-platelet function, and whether this could relate to blood clot risk. It includes detailed blood and stool/colonoscopy-related testing in adults with ulcerative colitis and in some people without it.
This trial tests if combining two medicines, vedolizumab and tofacitinib, helps control moderate to severe ulcerative colitis. It may be an option if other treatments, like anti-TNF drugs, haven't worked well for you.
This study is for people who already completed 52 weeks of treatment with TAK-279 for ulcerative colitis or Crohn's disease and saw improvement. It gives them the option to continue the medication long-term to see if the benefits last.
This trial tests whether people with ulcerative colitis who are in deep remission (no symptoms and healed gut lining) can safely stop taking their JAK inhibitor (tofacitinib, upadacitinib, or filgotinib) instead of continuing the usual maintenance dose. It aims to see if stopping is as effective and safer over time.
This trial tests if combining two medications, infliximab and tofacitinib, works better than standard treatment for adults hospitalized with a severe flare of ulcerative colitis. If you have not been on these drugs before and meet certain health criteria, you may be able to join.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.